TRM13 Antibody

What is TRMT13 and what are its primary functions in human cells?

TRMT13 (also known as CCDC76) is a tRNA methyltransferase that catalyzes 2'-O-methylation at the 4th position of specific tRNAs. It primarily methylates cytidine(4) in tRNA(Pro) and tRNA(Gly)(GCC), and adenosine(4) in tRNA(His) . Recent research has revealed that hTrmt13 (human TRMT13) plays a dual role in cellular function:

• As a tRNA-modifying enzyme that catalyzes the 2'-O-methylation (Nm4) of specific tRNAs

• As a transcriptional regulator that can modulate gene expression independent of its interaction with tRNAs

TRMT13 contains two zinc-finger domains (CCCH, Zn-1; CHHC, Zn-2), a coiled-coil domain, and a SAM-methyltransferase domain that are critical for its function . Research has shown that the CHHC Zn-2 domain is particularly crucial for TRMT13 binding to tRNA .

What are the most effective applications for TRMT13 antibodies in molecular biology research?

TRMT13 antibodies have proven effective in several key applications:

• Western blot analysis - For detecting and quantifying TRMT13 protein levels in cell or tissue lysates

• Immunoprecipitation - For isolating TRMT13 and its binding partners

• Immunofluorescence - For examining cellular localization patterns

• ChIP assays - For investigating the role of TRMT13 in transcriptional regulation

• CLIP-seq experiments - For identifying RNA binding patterns and substrates

How can I validate the specificity of my TRMT13 antibody?

Validating antibody specificity is critical for reliable research results. For TRMT13 antibodies, consider these validation approaches:

• Genetic knockout/knockdown validation: Compare antibody signal between wild-type cells and TRMT13 knockout or knockdown cells. Research has demonstrated the creation of TRMT13-KO cells using CRISPR-Cas9 system that can serve as excellent negative controls .

• Recombinant protein controls: Test antibody reactivity against purified recombinant TRMT13 protein.

• Peptide competition assay: Pre-incubate the antibody with the immunizing peptide to confirm signal specificity.

• Multiple antibody comparison: Use antibodies targeting different epitopes of TRMT13 to confirm consistent detection patterns.

• Mass spectrometry verification: Confirm the identity of immunoprecipitated proteins by mass spectrometry analysis.

How can TRMT13 antibodies be used to investigate the relationship between tRNA modification and protein translation?

TRMT13 antibodies can be powerful tools for investigating the functional relationship between tRNA modification and protein translation through several sophisticated approaches:

• Polysome profiling: Researchers have demonstrated that TRMT13 knockdown reduces polysome levels, suggesting decreased protein synthesis . By comparing polysome profiles between wild-type and TRMT13-depleted cells, researchers can assess translation efficiency differences.

• Puromycin incorporation assays: Studies have shown that TRMT13 knockdown cells display approximately 13-15% lower rates of puromycin incorporation compared to control cells . This reduction can be rescued by expressing wild-type TRMT13 but not catalytically inactive mutants (e.g., E463A) .

• tRNA modification analysis: Using TRMT13 antibodies for immunoprecipitation followed by RNA-mass spectrometry to analyze tRNA modifications. Research has shown that TRMT13 knockout significantly reduces Um/G values in specific tRNAs - to 34%, 46%, and 11% of wild-type levels in HctRNA Gly(GCC), HctRNA Gly(UCC), and HctRNA Pros, respectively .

• tRNA fragment (tRF) analysis: TRMT13 appears to regulate the levels of specific tRNA fragments, particularly 5'-Gly-CCC, which can inhibit protein synthesis . Quantitative RT-PCR assays using stem-loop primers have been successfully employed to detect these fragments.

What methodological approaches can be used to study the dual function of TRMT13 in tRNA modification and transcriptional regulation?

The dual functionality of TRMT13 presents unique investigative challenges requiring specialized methodological approaches:

• CLIP-seq with AlkB treatment: To study RNA interactions, UV cross-linking and immunoprecipitation followed by high-throughput sequencing (CLIP-seq) after RNA modifications are removed by AlkBs has proven effective . This method revealed that approximately 70% of TRMT13-bound RNAs are tRNAs .

• Domain-specific functional analysis: Structure-function studies using domain deletions have revealed distinct roles for TRMT13's domains. For example, deletion of the CHHC Zn-2 domain abolishes tRNA binding and catalytic activity, while deletion of CCCH Zn-1 doesn't affect these functions .

• Chromatin association studies: To investigate transcriptional regulatory functions, techniques like ChIP-seq can map TRMT13 chromatin binding sites.

• Mutant complementation assays: Expression of catalytically inactive TRMT13 mutants (e.g., E463A) in knockdown cells can help differentiate between methyltransferase-dependent and independent functions .

What are the critical controls needed when using TRMT13 antibodies in cancer research studies?

When investigating TRMT13 in cancer contexts, several critical controls are necessary:

• Cell type-specific expression profiling: TRMT13 expression varies across tissues and cancer types. Bioinformatic analyses from databases like TCGA have revealed associations between TRMT13 expression and patient survival in breast carcinoma, liver, and renal cancers .

• Correlation with established cancer markers: For example, research has demonstrated a positive correlation between TRMT13 and eukaryotic initiation factor 4A2 (EIF4A2) expression in breast cancer patients .

• Functional rescue controls: When studying TRMT13 knockdown phenotypes, complementation with wild-type versus catalytically inactive mutants is essential. Studies have shown that wild-type TRMT13, but not the E463A mutant, can rescue protein synthesis defects in knockdown cells .

• Tissue microarray validation: When examining TRMT13 expression across tumor samples, appropriate normal tissue controls and validation across multiple patient cohorts are necessary.

What are common pitfalls when using TRMT13 antibodies for Western blotting, and how can they be addressed?

Several technical challenges can arise when using TRMT13 antibodies for Western blotting:

• Multiple band detection: TRMT13 has reported isoforms (up to 2 different isoforms) , which may appear as multiple bands. Additionally, post-translational modifications can alter migration patterns.

  Solution: Include positive controls (recombinant protein) and negative controls (knockout lysates). Consult literature for expected band patterns.

• Low signal intensity: TRMT13 may be expressed at low levels in some cell types.

  Solution: Increase protein loading (50-100 μg total protein), optimize antibody concentration, and consider enhanced chemiluminescence detection systems.

• Non-specific binding: Background bands can complicate interpretation.

  Solution: Optimize blocking conditions (5% non-fat milk or BSA), include longer washing steps, and consider using more stringent washing buffers.

• Sample preparation issues: Improper lysis can affect TRMT13 detection.

  Solution: Use RIPA buffer with protease inhibitors for complete extraction. Consider nuclear extraction protocols if studying transcriptional functions.

How can researchers optimize CLIP-seq protocols when studying TRMT13-RNA interactions?

CLIP-seq optimization for TRMT13-RNA interaction studies requires attention to several methodological details:

• RNA modification removal: Since TRMT13 interacts with modified tRNAs, pre-treatment with AlkB enzymes has been shown to improve RNA recovery and sequence analysis .

• Crosslinking optimization: UV crosslinking efficiency varies between proteins and their RNA substrates.

  Solution: Optimize UV exposure times (typically 150-400 mJ/cm²) and consider using photoactivatable ribonucleoside-enhanced CLIP (PAR-CLIP) for improved crosslinking.

• RNase digestion: Over-digestion can lose valuable interaction information while under-digestion complicates mapping.

  Solution: Titrate RNase concentration and treatment time. Research has shown that optimized RNase treatment is critical for capturing the correct tRNA binding profile of TRMT13 .

• Library preparation: tRNAs have extensive secondary structures that can complicate reverse transcription.

  Solution: Use thermostable reverse transcriptases and include RNA denaturation steps. Consider specialized adapter ligation protocols designed for structured RNAs.

How do TRMT13-mediated tRNA modifications influence stress response pathways and translational control?

TRMT13's role in stress response and translational control presents intriguing research directions:

• tRNA fragment regulation: Research has shown that TRMT13 influences the levels of specific tRNA fragments, such as 5'-Gly-CCC, which increase in TRMT13 knockdown cells . These fragments can inhibit protein synthesis in a concentration-dependent manner .

• Stress granule dynamics: TRMT13 may influence stress granule formation and composition through its impact on translation and tRNA metabolism.

  Experimental approach: Immunofluorescence co-localization studies with stress granule markers following stress induction in TRMT13 wild-type versus depleted cells.

• Selective mRNA translation: TRMT13-mediated tRNA modifications might preferentially impact the translation of specific mRNA subsets.

  Experimental approach: Ribosome profiling in TRMT13 knockdown versus control cells, followed by analysis of codon usage patterns in differentially translated mRNAs.

• Integrated stress response: Investigation of potential crosstalk between TRMT13 and integrated stress response proteins (e.g., eIF2α phosphorylation).

What are the most effective approaches for investigating TRMT13's chromatin association and transcriptional regulatory functions?

To study TRMT13's emerging role in transcriptional regulation, these approaches are recommended:

• ChIP-seq optimization: Standard ChIP-seq protocols may require optimization for TRMT13.

  Recommendations:

  • Test multiple crosslinking conditions (formaldehyde concentration and time)

  • Compare different sonication parameters for optimal chromatin fragmentation

  • Include appropriate controls (IgG, input chromatin)

  • Validate binding sites with orthogonal methods (e.g., ChIP-qPCR)

• Proteomics identification of chromatin-associated complexes: Identify TRMT13's protein partners in chromatin-associated complexes.

  Approach: Conduct immunoprecipitation under conditions that preserve native chromatin interactions, followed by mass spectrometry analysis.

• CUT&RUN or CUT&Tag: These newer techniques offer higher resolution and lower background than traditional ChIP, potentially revealing TRMT13 binding sites with greater precision.

• Nascent transcription analysis: Methods like NET-seq (Native Elongating Transcript sequencing) can directly measure transcriptional impacts of TRMT13 depletion or mutation.

How can TRMT13 antibodies be utilized in biomarker development for cancer prognosis?

TRMT13's association with patient survival in certain cancers suggests potential as a prognostic biomarker:

• Tissue microarray analysis: TRMT13 antibodies can be used for immunohistochemical staining of tumor microarrays to correlate expression with clinical outcomes. Research has already identified associations between TRMT13 expression and patient survival in breast carcinoma, liver, and renal cancers .

• Multi-marker panels: TRMT13 could be incorporated into multi-marker panels for improved prognostic accuracy. The observed correlation between TRMT13 and EIF4A2 in breast cancer suggests potential combinatorial biomarker approaches .

• Validation requirements:

  • Independent patient cohorts

  • Standardized staining protocols

  • Quantitative scoring systems

  • Multivariate analysis controlling for known prognostic factors

• Liquid biopsy potential: Exploration of circulating tumor cell analysis for TRMT13 expression as a less invasive biomarker approach.

What methodological considerations are important when developing therapeutic targeting strategies against TRMT13?

If considering TRMT13 as a therapeutic target, several methodological approaches should be evaluated:

• Catalytic site inhibition: The E463A mutation has been identified as disrupting catalytic activity . Structure-based drug design targeting this region could yield selective inhibitors.

• Domain-specific targeting: The CHHC Zn-2 domain is essential for tRNA binding . Compounds disrupting this interaction could selectively inhibit tRNA modification without affecting other functions.

• Screening methodologies:

  • Development of high-throughput tRNA methylation assays

  • Cell-based reporter systems that monitor translation efficiency

  • Fragment-based screening against recombinant TRMT13 domains

• Target validation approaches:

  • Domain-specific mutagenesis comparing phenotypes of catalytic versus binding mutants

  • Inducible expression systems for controlled complementation studies

  • Animal models with tissue-specific TRMT13 depletion